RecruitingPhase 4NCT06475105

Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure Outcomes

Effects of Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure


Sponsor

Universitas Diponegoro

Enrollment

66 participants

Start Date

Apr 20, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Based on ADVOR trial, the potential of adding acetazolamide in increasing the success of decongestion, the amount of natriuresis and diuresis. However, the use of intravenous acetazolamide may not be possible in Indonesia, where the intravenous formulation is not available. This clinical research study is being conducted in single hospitals in Indonesia. We aim to learn if Oral Acetazolamide in addition to Furosemide intravenous works to treat congestion in Acute Decompensated Heart Failure, besides evaluating the total urinary output, change of NT pro BNP level, and safety profile of oral Acetazolamide. The hypothesis of this study is oral acetazolamide works well to achieve successful decongestion.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a combination of two diuretics (water pills) — oral acetazolamide and intravenous furosemide — works better than furosemide alone for people admitted to the hospital with worsening heart failure. When the heart is not pumping well, fluid builds up in the body, and diuretics help the kidneys remove that excess fluid. This study wants to know if the combination is more effective. **You may be eligible if...** - You have been diagnosed with acute worsening heart failure with signs of fluid buildup (such as leg swelling, fluid around the lungs, or belly fluid) - You have been taking oral diuretics (at least 40 mg furosemide) for at least 1 month - Your heart failure marker (NT-proBNP) is significantly elevated **You may NOT be eligible if...** - You have an acute heart attack (acute coronary syndrome) or are in cardiogenic shock - Your kidney function is severely reduced (eGFR < 20 mL/min) - You are on dialysis or kidney replacement therapy - You have had acetazolamide within the past month - You are pregnant or breastfeeding - You have congenital heart disease requiring surgery Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOral Acetazolamide

Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days

DRUGPlacebo

Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days


Locations(2)

Department of Cardiology and Vascular Medicine, Universitas Diponegoro, Kariadi Central General Hospital

Semarang, Central Java, Indonesia

Kariadi Central General Hospital

Semarang, Central Java, Indonesia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06475105


Related Trials